InDevR Ships First Multiplexed COVID-19 Serology Test Kits for Clinical ValidationBoulder, CO-9 April 2020– InDevR, Inc., a leader in progressive analytical technologies to support the development and production of ... Read More
InDevR Raises $7 million in Series A Financing with Adjuvant CapitalBoulder, CO, 10 September 2019 – InDevR, Inc., a biotechnology company focused on developing and commercializing novel analytical technologies ... Read More
Clinical validation of the FluChip-8G Influenza A+B Assay for influenza type and subtype identification published in Journal of Clinical Virology Go to Abstract ... Read More
Analytical Evaluation of the Microarray-Based FluChip-8G Influenza A+B Assay published in Journal of Virological Methods Go to Abstract ... Read More
ASM Microbe 2019InDevR will be present at the ASM conference in San Francisco in June. Rose Nash will be offering a presentation, "Assessment of the Correlation between Alternative Influenza ... Read More
510(k) Market Clearance for FluChip-8G Influenza A+B AssayInDevR receives 510(k) market clearance for the first influenza diagnostic assay capable of distinguishing between seasonal and non-seasonal influenza A subtypes ... Read More
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.